Amgen drug beats osteoporosis standard

The New England Journal of Medicine on September 11 epublished the results of a trial of more than 4000 postmeno­pausal women with osteoporosis and a previous fragility fracture, in which a monoclonal antibody made by Thousand Oaks, CA-based Amgen outperformed a commonly used and effective osteoporosis medication in preventing new fractures.

read more

Join

Subscribe For Updates

Stay in the loop with the latest news and updates! Subscribe now to receive exclusive content, special offers, and important announcements straight to your inbox. Don’t miss out – join our community today for all the latest updates delivered directly to you.